MENU
Menu
Share 2016-09-29 10:15 RATOS B 40.62 SEK

Christina Rubenhag new CEO of Biolin Scientific

2016-03-08

This information is disclosed pursuant to the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act or requirements stipulated in the listing agreement.

Christina Rubenhag has been appointed new CEO of Biolin Scientific, an international provider that develops, manufactures and markets analytical instruments for research, development and quality control. Johan von Heijne will step down after three years as CEO.

Biolin Scientific offers advanced analytical instruments for research and development that help scientists and enterprises to scientifically analyse materials, nanotechnologies and pharmaceuticals faster and better. Operations are divided into two separate business areas: Analytical Instruments and Drug Discovery. The Board of Biolin Scientific has decided to concentrate on each individual business area's strategic development. In conjunction with this, Group-wide resources will be limited and the Board has appointed Christina as new CEO. Christina has worked at Biolin Scientific since 2012 and she will replace Johan von Heijne who will step down due to the change. Johan has during his three years as CEO contributed to the company's strengthened positions.

"In recent years, Biolin Scientific has invested in product innovation and strengthening its market positions within the respective business areas. We want to continue to develop the evident potential within the segments. In line with this, the Board of Biolin Scientific has chosen to limit the Group-wide resources and appoint Christina, currently CFO, as new CEO. Christina has excellent insight into the company and will, together with the management team, continue to develop the offering and increase sales," says Susanna Campbell, CEO of Ratos.

Biolin Scientific was acquired in 2010. The company has about 115 employees, reported sales of SEK 227m in 2015 and an adjusted operating profit (EBITA) of SEK 8m.

For questions, please contact:
Henrik Joelsson, Investment Director, +46 8 700 17 00
Elin Ljung, Head of Corporate Communications, +46 8 700 17 20